Literature DB >> 23299311

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.

Bin Zhang1, Min Li, Tinisha McDonald, Tessa L Holyoake, Randall T Moon, Dario Campana, Leonard Shultz, Ravi Bhatia.   

Abstract

Tyrosine kinase inhibitors (TKIs) are highly effective in treatment of chronic myeloid leukemia (CML) but do not eliminate leukemia stem cells (LSCs), which remain a potential source of relapse. TKI treatment effectively inhibits BCR-ABL kinase activity in CML LSCs, suggesting that additional kinase-independent mechanisms contribute to LSC preservation. We investigated whether signals from the bone marrow (BM) microenvironment protect CML LSCs from TKI treatment. Coculture with human BM mesenchymal stromal cells (MSCs) significantly inhibited apoptosis and preserved CML stem/progenitor cells following TKI exposure, maintaining colony-forming ability and engraftment potential in immunodeficient mice. We found that the N-cadherin receptor plays an important role in MSC-mediated protection of CML progenitors from TKI. N-cadherin-mediated adhesion to MSCs was associated with increased cytoplasmic N-cadherin-β-catenin complex formation as well as enhanced β-catenin nuclear translocation and transcriptional activity. Increased exogenous Wnt-mediated β-catenin signaling played an important role in MSC-mediated protection of CML progenitors from TKI treatment. Our results reveal a close interplay between N-cadherin and the Wnt-β-catenin pathway in protecting CML LSCs during TKI treatment. Importantly, these results reveal novel mechanisms of resistance of CML LSCs to TKI treatment and suggest new targets for treatment designed to eradicate residual LSCs in CML patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23299311      PMCID: PMC3591802          DOI: 10.1182/blood-2012-02-412890

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells.

Authors:  Liqing Jin; Kristin J Hope; Qiongli Zhai; Florence Smadja-Joffe; John E Dick
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

2.  beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.

Authors:  Y Hu; Y Chen; L Douglas; S Li
Journal:  Leukemia       Date:  2008-09-25       Impact factor: 11.528

3.  CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.

Authors:  Linhua Jin; Yoko Tabe; Sergej Konoplev; Yuanyuan Xu; Clinton E Leysath; Hongbo Lu; Shinya Kimura; Akimichi Ohsaka; Mary-Beth Rios; Leslie Calvert; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Mol Cancer Ther       Date:  2008-01       Impact factor: 6.261

4.  Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.

Authors:  Heiko Konig; Mhairi Copland; Su Chu; Richard Jove; Tessa L Holyoake; Ravi Bhatia
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

5.  Assaying beta-catenin/TCF transcription with beta-catenin/TCF transcription-based reporter constructs.

Authors:  Travis L Biechele; Randall T Moon
Journal:  Methods Mol Biol       Date:  2008

6.  beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells.

Authors:  Marit Kveine Nygren; Guri Døsen-Dahl; Heidi Stubberud; Sébastien Wälchli; Else Munthe; Edith Rian
Journal:  Exp Hematol       Date:  2008-12-20       Impact factor: 3.084

Review 7.  Wnt-related molecules and signaling pathway equilibrium in hematopoiesis.

Authors:  Sachin Malhotra; Paul W Kincade
Journal:  Cell Stem Cell       Date:  2009-01-09       Impact factor: 24.633

8.  N-cadherin expression level distinguishes reserved versus primed states of hematopoietic stem cells.

Authors:  Jeffrey S Haug; Xi C He; Justin C Grindley; Joshua P Wunderlich; Karin Gaudenz; Jason T Ross; Ariel Paulson; Kathryn P Wagner; Yucai Xie; Ruihong Zhu; Tong Yin; John M Perry; Mark J Hembree; Erin P Redenbaugh; Glenn L Radice; Christopher Seidel; Linheng Li
Journal:  Cell Stem Cell       Date:  2008-04-10       Impact factor: 24.633

9.  BCR-ABL-transformed GMP as myeloid leukemic stem cells.

Authors:  Yosuke Minami; Scott A Stuart; Tomokatsu Ikawa; Yong Jiang; Asoka Banno; Irina C Hunton; Dennis J Young; Tomoki Naoe; Cornelis Murre; Catriona H M Jamieson; Jean Y J Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-11       Impact factor: 11.205

10.  Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.

Authors:  Nadine N Bewry; Rajesh R Nair; Michael F Emmons; David Boulware; Javier Pinilla-Ibarz; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

View more
  126 in total

Review 1.  A hostel for the hostile: the bone marrow niche in hematologic neoplasms.

Authors:  Daniela S Krause; David T Scadden
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

Review 2.  The Wnt signaling pathway in cancer.

Authors:  Yann Duchartre; Yong-Mi Kim; Michael Kahn
Journal:  Crit Rev Oncol Hematol       Date:  2015-12-24       Impact factor: 6.312

Review 3.  Inhibition of Ras-mediated signaling pathways in CML stem cells.

Authors:  Jessika Bertacchini; Neda Ketabchi; Laura Mediani; Silvano Capitani; Sandra Marmiroli; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-10-12       Impact factor: 6.730

4.  Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.

Authors:  Xiaoyan Zhang; Huaijun Tu; Yazhi Yang; Xiaoyan Jiang; Xianliang Hu; Qidong Luo; Jian Li
Journal:  J Biol Chem       Date:  2019-06-24       Impact factor: 5.157

5.  Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling.

Authors:  Heather A Himburg; Martina Roos; Tiancheng Fang; Yurun Zhang; Christina M Termini; Lauren Schlussel; Mindy Kim; Amara Pang; Jenny Kan; Liman Zhao; Hyung Suh; Joshua P Sasine; Gopal Sapparapu; Peter M Bowers; Gary Schiller; John P Chute
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

6.  Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia.

Authors:  Blake S Moses; Rebecca Evans; William L Slone; Debbie Piktel; Ivan Martinez; Michael D Craig; Laura F Gibson
Journal:  Mol Cancer Res       Date:  2016-06-29       Impact factor: 5.852

7.  Role of MSC-derived galectin 3 in the AML microenvironment.

Authors:  Peter P Ruvolo; Vivian R Ruvolo; Jared K Burks; YiHua Qiu; Rui-Yu Wang; Elizabeth J Shpall; Leonardo Mirandola; Numsen Hail; Zhihong Zeng; Teresa McQueen; Naval Daver; Sean M Post; Maurizio Chiriva-Internati; Steven M Kornblau; Michael Andreeff
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-04-12       Impact factor: 4.739

8.  High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia.

Authors:  Xiaoyan Zhang; Huaijun Tu; Yazhi Yang; Qian Wan; Lijun Fang; Qiong Wu; Jian Li
Journal:  Int J Hematol       Date:  2016-06-06       Impact factor: 2.490

9.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

Authors:  Bing Z Carter; Po Yee Mak; Duncan H Mak; Yuexi Shi; Yihua Qiu; James M Bogenberger; Hong Mu; Raoul Tibes; Hui Yao; Kevin R Coombes; Rodrigo O Jacamo; Teresa McQueen; Steven M Kornblau; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

10.  Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.

Authors:  Hai-Hong Zhang; Zhi-Yi Zhang; Chun-Li Che; Yi-Fang Mei; Yu-Zhi Shi
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.